Deciphera Pharmaceuticals, Inc.
DCPHN/A
NASDAQBiotechnology🇺🇸North America
Drugs in Pipeline
7
Phase 3 Programs
4
Upcoming Catalysts
3
Next Catalyst
Jul 15, 2026
17wMarket Overview
Stock performance and key metrics
DCPH News
Catalyst Timeline
3 upcoming, 0 past
Drug Pipeline
Sunitinib
Gastrointestinal Stromal Tumors
Ripretinib
GIST
Vimseltinib
Chronic Graft-Versus-Host Disease (cGVHD)
DCC-2618
Gastrointestinal Stromal Tumors
DCC-3084
Advanced Solid Tumor
DCC-3009
Gastrointestinal Stromal Tumor (GIST)
Inlexisertib
Non-Small Cell Lung Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Sunitinib | Phase 3 | Gastrointestinal Stromal Tumors | - | - |
Ripretinib | Phase 3 | GIST | - | - |
Vimseltinib | Phase 3 | Chronic Graft-Versus-Host Disease (cGVHD) | - | - |
DCC-2618 | Phase 3 | Gastrointestinal Stromal Tumors | - | - |
DCC-3084 | Phase 2 | Advanced Solid Tumor | - | - |
DCC-3009 | Phase 2 | Gastrointestinal Stromal Tumor (GIST) | - | - |
Inlexisertib | Phase 2 | Non-Small Cell Lung Cancer | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply